Zelira Therapeutics (ASX:ZLD) Stock Based Compensation: A$0.00 Mil (TTM As of Jun. 2025)


What is Zelira Therapeutics Stock Based Compensation?

Zelira Therapeutics ASX:ZLD Stock Based Compensation is A$0.00 Mil as of Jun. 2025. The stock has 7 warning signs investors should review.

Zelira Therapeutics's Stock Based Compensation for the six months ended in Jun. 2025 was A$0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2025 was A$0.00 Mil.

Zelira Therapeutics Stock Based Compensation Related Terms

Zelira Therapeutics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Zelira Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zelira Therapeutics Stock Based Compensation Chart

Zelira Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Zelira Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Zelira Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

What does a Stock Based Compensation of A$0.00 Mil mean?
Zelira Therapeutics (ASX:ZLD) has a Stock Based Compensation of A$0.00 Mil as of Jun. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Zelira Therapeutics and its competitors.
Is Zelira Therapeutics' Stock Based Compensation too high?
Zelira Therapeutics' current Stock Based Compensation is A$0.00 Mil.
How does Zelira Therapeutics' Stock Based Compensation compare to MTNB and SXTP?
Zelira Therapeutics' Stock Based Compensation of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Zelira Therapeutics and its competitors. Zelira Therapeutics's current Stock Based Compensation is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelira Therapeutics stock overvalued right now?
Zelira Therapeutics (ASX:ZLD) has a current Stock Based Compensation of A$0.00 Mil. The stock's GF Value™ is A$0.12, compared to a current price of A$0.50 — trading 316.7% above its estimated fair value. The current Stock Based Compensation is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Zelira Therapeutics (ASX:ZLD), the current Stock Based Compensation is A$0.00 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zelira Therapeutics Business Description

Other Exchanges ZLDAF:USA
Address 101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.